Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial


Curatolo P., Franz D. N. , Lawson J. A. , Yapici Z. , Ikeda H., Polster T., ...Daha Fazla

LANCET CHILD & ADOLESCENT HEALTH, cilt.2, sa.7, ss.495-504, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 2 Konu: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/s2352-4642(18)30099-3
  • Dergi Adı: LANCET CHILD & ADOLESCENT HEALTH
  • Sayfa Sayıları: ss.495-504

Özet

Background Epilepsy occurs in 70-90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study.